Adjust assumptions
Adjust the usable peer mix to see how each valuation multiple moves the blended fair value.
Peer-implied fair value
—
Blended value per share under the current mix.
Current price
—
Market price unavailable
Peer gap
N/A
Peer gap unavailable
Weighting mixer
No usable valuation methods are available for this peer set.
Value contribution
6 peers →Assign weight to at least one usable method to see the contribution split.
Equal-weight baseline
The simple average of every usable peer method, before your weighting adjustments.
Baseline equity value
—
Baseline / share
—
Relative valuation prices this company against what the market already pays for its peers. For a cash-flow view that does not inherit peer sentiment, open the intrinsic model.
Spreadsheet data
Audit the saved peer set and the method inputs behind the blended fair value.
The saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market cap | Enterprise value | Revenue | EBITDA |
|---|
| Net income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
ABBV AbbVie Inc. FY ended Feb 10, 2026 | — | — | — | $61.16B | $17.62B | $4.23B | — | — | — |
AMGN AMGEN INC FY ended Feb 10, 2026 | — | — | — | $36.75B | $14.04B | $7.71B | — | — | — |
BMY BRISTOL MYERS SQUIBB CO FY ended Feb 04, 2026 | — | — | — | $48.19B | $14.61B | $7.05B | — | — | — |
MRK Merck & Co., Inc. FY ended Jan 31, 2026 | — | — | — | $65.01B | $28.05B | $18.25B | — | — | — |
PFE PFIZER INC FY ended Feb 19, 2026 | — | — | — | $62.58B | $15.48B | $7.77B | — | — | — |
REGN REGENERON PHARMACEUTICALS, INC. FY ended Dec 31, 2025 | — | — | — | $14.34B | $5.62B | $4.50B | — | — | — |
ABBV
AbbVie Inc.
—
—
—
$61.16B
$17.62B
—
—
—
Cap —EV —Rev $61.16BEBITDA $17.62BP/E —P/S —EV/EBITDA —
AMGN
AMGEN INC
—
—
—
$36.75B
$14.04B
—
—
—
Cap —EV —Rev $36.75BEBITDA $14.04BP/E —P/S —EV/EBITDA —
BMY
BRISTOL MYERS SQUIBB CO
—
—
—
$48.19B
$14.61B
—
—
—
Cap —EV —Rev $48.19BEBITDA $14.61BP/E —P/S —EV/EBITDA —
MRK
Merck & Co., Inc.
—
—
—
$65.01B
$28.05B
—
—
—
Cap —EV —Rev $65.01BEBITDA $28.05BP/E —P/S —EV/EBITDA —
PFE
PFIZER INC
—
—
—
$62.58B
$15.48B
—
—
—
Cap —EV —Rev $62.58BEBITDA $15.48BP/E —P/S —EV/EBITDA —
REGN
REGENERON PHARMACEUTICALS, INC.
—
—
—
$14.34B
$5.62B
—
—
—
Cap —EV —Rev $14.34BEBITDA $5.62BP/E —P/S —EV/EBITDA —
Which peer averages feed the weighted fair value, and which methods are excluded.
| Method | Type | Avg. multiple | Coverage | Implied equity value | Fair value / share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | — | 0/6 | — | — | No saved peers have usable coverage for this method. |
Price / Sales PSExcluded | Equity Multiple | — | 0/6 | — | — | No saved peers have usable coverage for this method. |
Price / Earnings PEExcluded | Equity Multiple | — | 0/6 | — | — | No saved peers have usable coverage for this method. |
EV / EBITDA
EV · Enterprise Multiple
Avg. multiple
—
Coverage
0/6
Implied equity value
—
Fair value / share
—
No saved peers have usable coverage for this method.
Price / Sales
PS · Equity Multiple
Avg. multiple
—
Coverage
0/6
Implied equity value
—
Fair value / share
—
No saved peers have usable coverage for this method.
Price / Earnings
PE · Equity Multiple
Avg. multiple
—
Coverage
0/6
Implied equity value
—
Fair value / share
—
No saved peers have usable coverage for this method.
